Inovio Surrenders Some Early Gains After Positive HIV Vaccine Clinical Study

Inovio Pharmaceuticals Inc INO shares are trading higher by $2.00 (28 percent) at $9.13 in Wednesday's session.

The catalyst for the rally is announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response. The announcement made before the open instigated a spike to $12.00 during pre-market trading, which is a level not seen since November 2014.

However, investors began to unload shares.

By the open of the regular session, Inovio's stock was back at the $9.50 area and has done no better than $9.85 since 9:30 a.m. EST. The decline off that high found intraday support at $8.64 and is now back actively trading in the $9.00 handle.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!